Department of Radiation Oncology, Institut Curie, Paris, France.
Department of Radiology, Institut Curie, Paris, France.
Breast J. 2021 Nov;27(11):824-827. doi: 10.1111/tbj.14282. Epub 2021 Aug 25.
The COVID-19 caused by the SARS-CoV-2 coronavirus is at the origin of a global pandemic. This pandemic has prompted the current health system to reorganize and rethink the care offered by health establishments. We report the early toxicity in patients infected with COVID-19 treated at the same time for early-stage breast cancer (BC). This is a monocentric prospective study of patients treated in our hospital between March 2020 and June 2020 and were diagnosed with COVID-19 infection. The inclusion criteria were to be irradiated for early-stage BC and to have a positive COVID-19 diagnosis on a PCR test and/or a lung computed tomography (CT) scan and/or suggestive clinical symptoms. Radiotherapy (RT) consisted of breast or chest wall irradiation with or without lymph node irradiation, with protocols adapted to pandemic situation. The treatment-related toxicity was graded according to the CTCAE (version 4.03). All 350 patients treated for early-stage BC were studied. Of them, 16 were presented with clinical symptoms of COVID-19 infection and of them, 12 had clinical, CT scan, and PCR confirmation. This entire cohort of 12 pts with median age of 56 (42-72) underwent their RT. During the radiotherapy, there were 9 pts presented radiation dermatitis, 8 (66%) were grade 1 and one was (8%) grade 2. Two patients with lymph nodes irradiation presented esophagitis grade 2. This prospective COVID-19 cohort, treated for early-stage BC demonstrated an acceptable toxicity profile with few low-grade adverse events. Longer follow-up is needed to confirm these findings.
由严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）引起的 2019 年冠状病毒病（COVID-19）是全球大流行的根源。这场大流行促使当前的卫生系统进行重组和重新思考卫生机构提供的护理。我们报告了同时接受早期乳腺癌（BC）治疗的 COVID-19 感染患者的早期毒性。这是一项在 2020 年 3 月至 2020 年 6 月期间在我们医院接受治疗且被诊断为 COVID-19 感染的患者的单中心前瞻性研究。纳入标准为患有早期 BC 且 PCR 检测和/或肺部计算机断层扫描（CT）和/或提示临床症状呈阳性的患者。放射治疗（RT）包括乳房或胸壁照射，或联合淋巴结照射，方案适应大流行情况。根据 CTCAE（第 4.03 版）对治疗相关毒性进行分级。所有接受早期 BC 治疗的 350 例患者均进行了研究。其中，16 例患者出现 COVID-19 感染的临床症状，其中 12 例患者具有临床、CT 扫描和 PCR 确认。这整个 12 例患者队列的中位年龄为 56 岁（42-72 岁），接受了 RT。在放疗期间，有 9 例患者出现放射性皮炎，8 例（66%）为 1 级，1 例（8%）为 2 级。2 例接受淋巴结照射的患者出现 2 级食管炎。这项针对早期 BC 患者的前瞻性 COVID-19 队列研究显示出可接受的毒性特征，仅有少数低级别不良事件。需要更长时间的随访来证实这些发现。
